PT - JOURNAL ARTICLE AU - Atai, Nadia A. AU - Ravina, Kristine AU - Sizdahkhani, Saman AU - Rennert, Robert AU - Abedi, Aidin AU - Kress, Gavin T. AU - Fabris, Federico AU - Nguyen, Vincent AU - Louie, Stan G AU - Shin, Laura AU - Asante, Isaac AU - Hawes, Debra AU - Rossetto, Ornella AU - Carey, Joseph AU - Russin, Jonathan J. TI - Botulinum Toxin Application for Treatment of Graft Vasospasm: A Reverse Translational Study AID - 10.1101/2024.11.13.24317189 DP - 2024 Jan 01 TA - medRxiv PG - 2024.11.13.24317189 4099 - http://medrxiv.org/content/early/2024/11/13/2024.11.13.24317189.short 4100 - http://medrxiv.org/content/early/2024/11/13/2024.11.13.24317189.full AB - Vascular graft vasospasm is a lethal risk when using grafts for revascularization and reconstructive surgery. Revascularization is a treatment modality for ischemic diseases including Moyamoya disease that requires bypass surgery. Cerebrovascular graft transplantation carries a 5-10% risk of vasospasm, which can lead to devastating neurological sequelae. Here we report clinical outcomes associated with ex vivo botulinum toxin A (BoNT/A) treatment of arterial graft and provide reverse translational studies investigating the potential mechanisms of action of BoNT/A to reduce vasospasm. A retrospective review of the maintained database of patients undergoing surgery was performed for 63 patients. We used paired human vascular graft tissue for ex vivo BoNT/A studies to assess for spasmolytic downstream effectors; cleaved SNAP25, pMLC, pMYPT, ROCK1/2, and levels of catecholamines. We found that low-dose BoNT/A graft treatment is associated with 1) a reduction in clinical vasospasm (13.3%, p<0.05) without any identified safety concerns in patients, 2) an increase in arterial cleaved SNAP25, 3) reduced levels of pMLC and pMYPT, and 4) reduced levels of catecholamines. The mechanism of action leading to vascular relaxation is likely through pleiotropic vasodilatory pathways. The application of BoNT/A as a spasmolytic has potentially safe and broad applications across multiple surgical and scientific subspecialties.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis publication was made possible by National Institutes of Health R03 grant #5R03NS113090-02 (JJR) and the Alfred E. Mann Charities, Inc (JJR). Its contents are solely the responsibility of the authors. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:An IRB-approved (HS-18-00968, USC, University of Southern California), prospectively maintained database was used to identify and consent patients who had undergone EC-IC bypass with an autologous arterial interposition graft between July 2014 and January 2022. Interposition grafts were treated with BoNT/A beginning in March 2017. Information obtained included patient demographics, clinical presentation, indication for bypass, surgery performed, pre- and post-operative imaging characteristics, clinical outcomes (e.g., modified Rankin Scale [mRS] at follow-up), and complications.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors All data produced in the present work are contained in the manuscript5HIAA5-hydroxyindoleacetic acidBoNTbotulinum toxinDLCFAdescending branch of the lateral circumflex femoral arteryEC-ICextracranial-to-intracranialIglmmgeneralized linear mixed-level modelsIC-ICintracranial-to-intracranialIFimmunofluorescenceIHCimmunohistochemistryIQRinterquartile rangeLC-MSliquid chomotography-mass spectrometryMAPmean arterial pressuremRSmodified Rankin ScaleNTneurotransmitterpMLCphosphorylated myosin light chainpMYPT1phosphorylated myosin phosphatase target subunit 1RAFCFradial artery fasciocutaneous flow-through free flapRAFFradial artery fascial flow-through free flapRAGradial arteryrho kinaseROCK1/2SAHsubarachnoid hemorrhageSDstandard deviationSDSsodium dodecyl sulfateSNAP25synaptosomal-associated protein 25 kDaSRMselected reaction monitoringTBSTris-buffered salineTHtyrosine hydroxylaseVMAvanillylmandelic acidVSMCs: vascular smooth muscle cells.